RecruitingNCT06570980
Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.
Sponsor
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Enrollment
200 participants
Start Date
Aug 25, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The aim of this study is to compare the cost effectiveness of Sulfonylureas and DPP4-inhibitors in combination with Metformin among type2 diabetic patients diagnosed for 2-5 years. Glycemic status and other clinical outcome are compared in between two groups and ICER are compared.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- New onset type2 diabetes mellitus diagnosed for 2 -5 years.
- Taking either sulfonylurea or DPP4 inhibitors combined with Metformin from the time of diagnosis.
- Age 18 years or above.
- Both male and female.
- Provided written informed consent.
Exclusion Criteria4
- Unwillingness to participate or unwillingness to give written informed consent.
- Patients on Insulin therapy or monotherapy with metformin since the time of diagnosis.
- Taking other than sulfonylurea or DPP4 inhibitors combined with Metformin from the time of diagnosis.
- Diabetes related complications at the time of diagnosis.
Interventions
DRUGsulfonylurease with metformin, DPP4 inhibitors with Metformin
Oral hypoglycemic agents
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06570980